JP2021534110A5 - - Google Patents

Info

Publication number
JP2021534110A5
JP2021534110A5 JP2021506687A JP2021506687A JP2021534110A5 JP 2021534110 A5 JP2021534110 A5 JP 2021534110A5 JP 2021506687 A JP2021506687 A JP 2021506687A JP 2021506687 A JP2021506687 A JP 2021506687A JP 2021534110 A5 JP2021534110 A5 JP 2021534110A5
Authority
JP
Japan
Prior art keywords
hydrogen
optionally substituted
substituted substituent
pharmaceutical product
cancer
Prior art date
Application number
JP2021506687A
Other languages
English (en)
Japanese (ja)
Other versions
JP7530346B2 (ja
JP2021534110A (ja
JPWO2020033715A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/045742 external-priority patent/WO2020033715A1/en
Publication of JP2021534110A publication Critical patent/JP2021534110A/ja
Publication of JP2021534110A5 publication Critical patent/JP2021534110A5/ja
Publication of JPWO2020033715A5 publication Critical patent/JPWO2020033715A5/ja
Priority to JP2024120839A priority Critical patent/JP2024156758A/ja
Application granted granted Critical
Publication of JP7530346B2 publication Critical patent/JP7530346B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021506687A 2018-08-08 2019-08-08 癌及び自己免疫疾患を治療するための組成物及び方法 Active JP7530346B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024120839A JP2024156758A (ja) 2018-08-08 2024-07-26 癌及び自己免疫疾患を治療するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862716101P 2018-08-08 2018-08-08
US62/716,101 2018-08-08
PCT/US2019/045742 WO2020033715A1 (en) 2018-08-08 2019-08-08 Compositions and methods for treating cancer and autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024120839A Division JP2024156758A (ja) 2018-08-08 2024-07-26 癌及び自己免疫疾患を治療するための組成物及び方法

Publications (4)

Publication Number Publication Date
JP2021534110A JP2021534110A (ja) 2021-12-09
JP2021534110A5 true JP2021534110A5 (https=) 2022-08-02
JPWO2020033715A5 JPWO2020033715A5 (https=) 2022-08-02
JP7530346B2 JP7530346B2 (ja) 2024-08-07

Family

ID=69415674

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021506687A Active JP7530346B2 (ja) 2018-08-08 2019-08-08 癌及び自己免疫疾患を治療するための組成物及び方法
JP2024120839A Pending JP2024156758A (ja) 2018-08-08 2024-07-26 癌及び自己免疫疾患を治療するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024120839A Pending JP2024156758A (ja) 2018-08-08 2024-07-26 癌及び自己免疫疾患を治療するための組成物及び方法

Country Status (7)

Country Link
US (1) US20210299176A1 (https=)
EP (1) EP3833323A4 (https=)
JP (2) JP7530346B2 (https=)
KR (2) KR102753455B1 (https=)
CN (2) CN112739314A (https=)
CA (1) CA3108796A1 (https=)
WO (1) WO2020033715A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220370586A1 (en) * 2019-08-08 2022-11-24 Cedars-Sinai Medical Center Method of generating activated t cells for cancer therapy
CN113429488B (zh) * 2021-07-14 2022-08-30 海正生物制药有限公司 GITR/TGF-β双靶向融合蛋白及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ZA200509143B (en) * 2003-05-23 2007-03-28 Wyeth Corp GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
TW200800230A (en) * 2006-03-31 2008-01-01 Dynamis Therapeutics Inc Composition and method related to fructosamine-3-kinase inhibitors
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
SG10201912986PA (en) * 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
JP2018503373A (ja) * 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
PL3242947T3 (pl) 2015-01-09 2021-01-11 Oncosec Medical Incorporated Terapia genowa i elektroporacja do leczenia zmian złośliwych

Similar Documents

Publication Publication Date Title
US10463644B2 (en) Uses of sesquiterpene lactone compounds and their derivatives in drugs preparation
CA2938280C (en) 4-amino-imidazoquinoline compounds
Song et al. Base promoted synthesis of novel indole-dithiocarbamate compounds as potential anti-inflammatory therapeutic agents for treatment of acute lung injury
JP5992615B2 (ja) 抗癌剤であるシクロプロパンカルボキサミドで置換された芳香族化合物
CN109311854A (zh) 具有仲酰胺官能团的苯并氮杂卓二甲酰胺化合物
JP6155395B2 (ja) 新規ｄｇａｔ２阻害剤
US9056858B2 (en) Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists
JP2021534110A5 (https=)
ES2651484T3 (es) Compuesto heterocíclico que contiene nitrógeno
US11974997B2 (en) RORgamma modulators and uses thereof
EA028818B1 (ru) Производные амидов в качестве антагонистов рецептора к лизофосфатидной кислоте
CN106977581A (zh) 知母皂苷元结构修饰的衍生物、其药物组合物及其应用
BR112018014666B1 (pt) Compostos de 2-oxindol, seu uso e composição farmacêutica
TW200305417A (en) Chemical compounds
Wu et al. Discovery of 2-(4-Chloro-3-(trifluoromethyl) phenyl)-N-(4-((6, 7-dimethoxyquinolin-4-yl) oxy) phenyl) acetamide (CHMFL-KIT-64) as a novel orally available potent inhibitor against broad-spectrum mutants of c-KIT kinase for gastrointestinal stromal tumors
CN104151391B (zh) 一种具有抗肿瘤作用的齐墩果酸衍生物及其制备方法和用途
Li et al. Novel indole-guanidine hybrids as potential anticancer agents: Design, synthesis and biological evaluation
JPWO2020033715A5 (https=)
JPWO2013147216A1 (ja) （２−ヘテロアリールアミノ）コハク酸誘導体
CN104045680A (zh) 桦木醇的乙酰氨基酸酰类衍生物及其制备方法
CN104725389B (zh) 黑三棱内酯b衍生物及其制备方法和用途
EP4479054A1 (en) Compounds, compositions, and methods
CN106543194A (zh) 水仙环素衍生物及其制备与在制备抗肿瘤药物中的应用
Talati et al. Synthesis and immunomodulatory activity of novel amino acid analogues of fluoxetine
TW200524900A (en) Chemical compounds